This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Suzuki, T. Articles by Sasano, H. Search for Related Content PubMed PubMed Citation Articles by Suzuki, T. Articles by Sasano, H.

Estrogen Sulfotransferase and Steroid Sulfatase in Human Breast Carcinoma

Departments of Pathology [T. S., T. N., Y. M., C. K., T. M., H. S.] and Surgery [T. I.], Tohoku University School of Medicine, Sendai, 980-8575; Pharmaceuticals Company, Kyowa Hakko Kogyo Co. Ltd., Tokyo 100-8185 [T. N., S. A.]; and Department of Surgery, Tohoku Kosai Hospital, Sendai 980-0803 [H. H., M. K.], Japan

Estrogen sulfotransferase (EST; SULT 1E1 or STE gene) sulfonates estrogens to inactive estrogen sulfates, whereas steroid sulfatase (STS) hydrolyzes estrone sulfate to estrone. Both EST and STS have been suggested to play important roles in regulating the in situ production of estrogens in human breast carcinoma tissues. However, the expression of EST has not been examined in breast carcinoma tissues, and the biological significance of EST and STS remains unknown. Therefore, in this study, we examined the expression of EST and STS in 35 specimens of human breast carcinoma tissues using immunohistochemistry, reverse transcription-PCR (RT-PCR), and enzymatic assay. EST and STS immunoreactivity was also correlated with various clinicopathological parameters, including prognosis to examine the biological significance of these enzymes in 113 breast carcinomas. EST and STS immunoreactivity was detected in carcinoma cells and significantly associated with their mRNA levels (P = 0.0027 and 0.0158, respectively), as measured by RT/real-time PCR, and enzymatic activities (P = 0.0005 and 0.0089, respectively) in 35 breast carcinomas. In breast cancer tissues examined by laser capture microdissection/RT-PCR analyses, the mRNA for EST was localized in both carcinoma and intratumoral stromal cells, whereas that of STS was detected only in carcinoma cells. Of the 113 invasive ductal carcinomas examined in this study, EST and STS immunoreactivity was detected in 50 and 84 cases (44.2 and 74.3%), respectively. In these cases, EST immunoreactivity was inversely correlated with tumor size (P = 0.003) or lymph node status (P = 0.0027). In contrast, STS immunoreactivity was significantly correlated with tumor size (P = 0.0047). Moreover, EST immunoreactivity was significantly associated with a decreased risk of recurrence or improved prognosis by both uni (P = 0.0044, and 0.0026, respectively) and multivariate (P = 0.0429 and 0.0149, respectively) analyses. STS immunoreactivity, however, was significantly associated with an increased risk of recurrence (P = 0.0118) and worsened prognosis (P = 0.0325) by univariate analysis. Results from our present study suggest that immunoreactivities for both EST and STS are associated with their mRNA level and enzymatic activity and that EST immunoreactivity is considered to be a potent prognostic factor in human breast carcinoma.

This article has been cited by other articles:

				R. Shibuya, T. Suzuki, Y. Miki, K. Yoshida, T. Moriya, K. Ono, J.-i. Akahira, T. Ishida, H. Hirakawa, D. B Evans, et al. Intratumoral concentration of sex steroids and expression of sex steroid-producing enzymes in ductal carcinoma in situ of human breast Endocr. Relat. Cancer, March 1, 2008; 15(1): 113 - 124. [Abstract] [Full Text] [PDF]

				Y. Miki, T. Suzuki, C. Tazawa, Y. Yamaguchi, K. Kitada, S. Honma, T. Moriya, H. Hirakawa, D. B. Evans, S.-i. Hayashi, et al. Aromatase Localization in Human Breast Cancer Tissues: Possible Interactions between Intratumoral Stromal and Parenchymal Cells Cancer Res., April 15, 2007; 67(8): 3945 - 3954. [Abstract] [Full Text] [PDF]

				H. J. Kloosterboer, L. Lofgren, E. von Schoulz, B. von Schoultz, and H. A. M. Verheul Estrogen and Tibolone Metabolite Levels in Blood and Breast Tissue of Postmenopausal Women Recently Diagnosed With Early-Stage Breast Cancer and Treated With Tibolone or Placebo for 14 Days Reproductive Sciences, February 1, 2007; 14(2): 151 - 159. [Abstract] [PDF]

				S. Kobayashi, H. Kubo, T. Suzuki, K. Ishizawa, M. Yamada, M. He, Y. Yamamoto, H. Yamamoto, H. Sasano, H. Sasaki, et al. Endogenous Secretory Receptor for Advanced Glycation End Products in Non-Small Cell Lung Carcinoma Am. J. Respir. Crit. Care Med., January 15, 2007; 175(2): 184 - 189. [Abstract] [Full Text] [PDF]

				S. J. Stanway, A. Purohit, L.W. L. Woo, S. Sufi, D. Vigushin, R. Ward, R. H. Wilson, F. Z. Stanczyk, N. Dobbs, E. Kulinskaya, et al. Phase I Study of STX 64 (667 Coumate) in Breast Cancer Patients: The First Study of a Steroid Sulfatase Inhibitor Clin. Cancer Res., March 1, 2006; 12(5): 1585 - 1592. [Abstract] [Full Text] [PDF]

				N. Honma, K. Takubo, M. Sawabe, T. Arai, F. Akiyama, G. Sakamoto, T. Utsumi, N. Yoshimura, and N. Harada Estrogen-Metabolizing Enzymes in Breast Cancers from Women over the Age of 80 Years J. Clin. Endocrinol. Metab., February 1, 2006; 91(2): 607 - 613. [Abstract] [Full Text] [PDF]

				Y. Miki, T. Suzuki, K. Kitada, N. Yabuki, R. Shibuya, T. Moriya, T. Ishida, N. Ohuchi, B. Blumberg, and H. Sasano Expression of the Steroid and Xenobiotic Receptor and Its Possible Target Gene, Organic Anion Transporting Polypeptide-A, in Human Breast Carcinoma Cancer Res., January 1, 2006; 66(1): 535 - 542. [Abstract] [Full Text] [PDF]

				T. Suzuki, Y. Miki, Y. Nakamura, T. Moriya, K. Ito, N. Ohuchi, and H. Sasano Sex steroid-producing enzymes in human breast cancer Endocr. Relat. Cancer, December 1, 2005; 12(4): 701 - 720. [Abstract] [Full Text] [PDF]

				H. Ishibashi, T. Suzuki, S. Suzuki, T. Moriya, C. Kaneko, T. Nakata, M. Sunamori, M. Handa, T. Kondo, and H. Sasano Estrogen Inhibits Cell Proliferation through In situ Production in Human Thymoma Clin. Cancer Res., September 15, 2005; 11(18): 6495 - 6504. [Abstract] [Full Text] [PDF]

				T. Suzuki, T. Urano, T. Tsukui, K. Horie-Inoue, T. Moriya, T. Ishida, M. Muramatsu, Y. Ouchi, H. Sasano, and S. Inoue Estrogen-Responsive Finger Protein as a New Potential Biomarker for Breast Cancer Clin. Cancer Res., September 1, 2005; 11(17): 6148 - 6154. [Abstract] [Full Text] [PDF]

				J.-Y. Choi, K.-M. Lee, S. K. Park, D.-Y. Noh, S.-H. Ahn, H.-W. Chung, W. Han, J. S. Kim, S. G. Shin, I.-J. Jang, et al. Genetic Polymorphisms of SULT1A1 and SULT1E1 and the Risk and Survival of Breast Cancer Cancer Epidemiol. Biomarkers Prev., May 1, 2005; 14(5): 1090 - 1095. [Abstract] [Full Text] [PDF]

				M. J. Reed, A. Purohit, L. W. L. Woo, S. P. Newman, and B. V. L. Potter Steroid Sulfatase: Molecular Biology, Regulation, and Inhibition Endocr. Rev., April 1, 2005; 26(2): 171 - 202. [Abstract] [Full Text] [PDF]

				J. Lepine, O. Bernard, M. Plante, B. Tetu, G. Pelletier, F. Labrie, A. Belanger, and C. Guillemette Specificity and Regioselectivity of the Conjugation of Estradiol, Estrone, and Their Catecholestrogen and Methoxyestrogen Metabolites by Human Uridine Diphospho-glucuronosyltransferases Expressed in Endometrium J. Clin. Endocrinol. Metab., October 1, 2004; 89(10): 5222 - 5232. [Abstract] [Full Text] [PDF]

				H. Utsunomiya, K. Ito, T. Suzuki, T. Kitamura, C. Kaneko, T. Nakata, H. Niikura, K. Okamura, N. Yaegashi, and H. Sasano Steroid Sulfatase and Estrogen Sulfotransferase in Human Endometrial Carcinoma Clin. Cancer Res., September 1, 2004; 10(17): 5850 - 5856. [Abstract] [Full Text] [PDF]

				L. Lu, T. Suzuki, Y. Yoshikawa, O. Murakami, Y. Miki, T. Moriya, M. H. Bassett, W. E. Rainey, Y. Hayashi, and H. Sasano Nur-Related Factor 1 and Nerve Growth Factor-Induced Clone B in Human Adrenal Cortex and Its Disorders J. Clin. Endocrinol. Metab., August 1, 2004; 89(8): 4113 - 4118. [Abstract] [Full Text] [PDF]

				T. Suzuki, Y. Miki, T. Moriya, N. Shimada, T. Ishida, H. Hirakawa, N. Ohuchi, and H. Sasano Estrogen-Related Receptor {alpha} in Human Breast Carcinoma as a Potent Prognostic Factor Cancer Res., July 1, 2004; 64(13): 4670 - 4676. [Abstract] [Full Text] [PDF]

				R. M. Harris, D. M. Wood, L. Bottomley, S. Blagg, K. Owen, P. J. Hughes, R. H. Waring, and C. J. Kirk Phytoestrogens Are Potent Inhibitors of Estrogen Sulfation: Implications for Breast Cancer Risk and Treatment J. Clin. Endocrinol. Metab., April 1, 2004; 89(4): 1779 - 1787. [Abstract] [Full Text] [PDF]